Pfizer Inc. (PFE) Shares Sold by Navellier & Associates Inc
Navellier & Associates Inc reduced its position in Pfizer Inc. (NYSE:PFE) by 2.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,240 shares of the biopharmaceutical company’s stock after selling 266 shares during the period. Navellier & Associates Inc’s holdings in Pfizer were worth $344,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. K.J. Harrison & Partners Inc lifted its position in Pfizer by 11.9% during the 1st quarter. K.J. Harrison & Partners Inc now owns 48,639 shares of the biopharmaceutical company’s stock worth $1,664,000 after acquiring an additional 5,159 shares in the last quarter. Callahan Advisors LLC increased its holdings in Pfizer by 1.9% during the 1st quarter. Callahan Advisors LLC now owns 279,334 shares of the biopharmaceutical company’s stock worth $9,556,000 after purchasing an additional 5,176 shares during the last quarter. Beaumont Financial Partners LLC increased its holdings in Pfizer by 17.1% during the 1st quarter. Beaumont Financial Partners LLC now owns 8,597 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 1,254 shares during the last quarter. Grandfield & Dodd LLC increased its holdings in Pfizer by 0.3% during the 1st quarter. Grandfield & Dodd LLC now owns 83,230 shares of the biopharmaceutical company’s stock worth $2,847,000 after purchasing an additional 250 shares during the last quarter. Finally, Usca Ria LLC increased its holdings in Pfizer by 19.6% during the 1st quarter. Usca Ria LLC now owns 331,931 shares of the biopharmaceutical company’s stock worth $11,355,000 after purchasing an additional 54,492 shares during the last quarter. 69.89% of the stock is currently owned by institutional investors and hedge funds.
In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the transaction, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.
Several research firms have issued reports on PFE. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. J P Morgan Chase & Co set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. Jefferies Group set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Thursday, November 16th. Berenberg Bank set a $36.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, October 31st. Finally, Morgan Stanley upgraded Pfizer from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Pfizer currently has an average rating of “Buy” and an average target price of $38.77.
Shares of Pfizer Inc. (NYSE:PFE) opened at $37.20 on Friday. Pfizer Inc. has a twelve month low of $30.90 and a twelve month high of $37.22. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The firm has a market capitalization of $217,387.00, a P/E ratio of 14.59, a PEG ratio of 2.57 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same period in the previous year, the business earned $0.61 EPS. The business’s quarterly revenue was up .9% on a year-over-year basis. sell-side analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were issued a $0.32 dividend. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.44%. Pfizer’s dividend payout ratio (DPR) is 79.01%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.